Insulin human

Unknown / undisclosed

Approvedregulatory verdict

Evidence outlook

Approved: Type 1 Diabetes

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

Also approved (1)
US
  • HUMULIN R U-500 is a concentrated human insulin indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus requiring more than 200 units of insulin per day.
Product first approved 1982Outside this platform's coverageFDA label

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (2)
Other / comorbidity
NCT00071448 · Novo Nordisk A/S
2002-06 – 2004-06 · Diabetes, Diabetes Mellitus, Type 1
What this study did
Phase 2/3 (3)
Other / comorbidity
NCT01767909 · University of Southern California
2014-01-08 – 2018-12-11 · Amnestic Mild Cognitive Impairment, Alzheimer's Disease
What this study did
NCT00539409 · Florida Atlantic University
2006-11 – 2009-08 · Diabetes Mellitus, With Complications
What this study did
NCT01029639 · Florida Atlantic University
2007-01 – 2009-08 · Hypoglycemia
What this study did
Phase 2 (9)
Type 1 Diabetes
NCT05742243 · Melbourne Health
2023-02-13 – 2025-09-30 · Type 1 Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT04028960 · HealthPartners Institute
2019-10-23 – 2020-04-08 · Type1diabetes
What this study did
NCT02028078 · Medical University of Graz
2014-01 – 2016-03 · Type 1 Diabetes Mellitus
What this study did
NCT00774800 · Halozyme Therapeutics
2008-10 – 2009-03 · Type 1 Diabetes Mellitus
What this study did
Other / comorbidity
NCT05006599 · Wake Forest University Health Sciences
2025-05 – 2031-05 · Mild Cognitive Impairment, Cognitive Impairment, Alzheimer Disease, Early Onset
What this study did
NCT05081219 · Wake Forest University Health Sciences
2021-09-14 – 2024-09-17 · Mild Cognitive Impairment, Cognitive Impairment, Alzheimer Disease
What this study did
NCT06002854 · Jinnah Postgraduate Medical Centre
2022-08-01 – 2023-02-01 · ATROPHIC ACNE SCARS
What this study did
NCT04199767 · Wake Forest University Health Sciences
2020-07-16 – 2020-11-03 · Mild Cognitive Impairment, Cognitive Impairment
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT03915613 · University Health Network, Toronto
2021-10-06 – 2024-10-05 · Major Depressive Disorder, Bipolar Disorder, Anhedonia, Intranasal Insulin
What this study did
Phase 1 (14)
Type 1 Diabetes
NCT07341373 · Portal Diabetes, Inc.
2026-02-10 – 2026-09-30 · Type 1 Diabetes
What this study did
NCT01269606 · Novo Nordisk A/S
2011-01 – 2011-03 · Diabetes, Diabetes Mellitus, Type 1
What this study did
Other / comorbidity
NCT06558422 · Columbia University
2027-01-01 – 2029-02-28 · Insulin Resistance, Hyperinsulinemia, Metabolic Dysfunction Associated Steatotic Liver Disease, Non-Alcoholic Fatty Liver Disease, Prediabetic State, Obesity
What this study did
NCT06126354 · Columbia University
2024-07-01 – 2026-03-31 · Insulin Resistance, Prediabetic State, Non-Alcoholic Fatty Liver Disease, Overweight and Obesity
What this study did
NCT05724134 · Columbia University
2023-08-29 – 2025-09-24 · Insulin Resistance, Prediabetic State, Hyperinsulinemia, Non-Alcoholic Fatty Liver Disease, Obesity
What this study did
NCT05754424 · Arecor Limited
2023-02-27 – 2024-02-12 · Diabetes Mellitus, Type 2
What this study did
NCT02729064 · Hiroaki Sato, MD., PhD.
2016-09 – 2021-09 · Ischemic Heart Disease, Aortic Aneurysm
What this study did
NCT01358435 · Wockhardt
2011-01 – 2011-05 · Diabetes Mellitus
What this study did
NCT00752180 · Wockhardt
2008-08 – 2009-04 · Diabetes
What this study did
NCT00719108 · Wockhardt
2008-07 – 2008-09 · Diabetes
What this study did
NCT00596063 · Wockhardt
2008-01 – 2008-02 · Diabetes Mellitus
What this study did
Phase 4 (6)
Type 1 Diabetes
NCT05768191 · Université NAZI BONI
2023-06-15 – 2024-05-01 · Type 1 Diabetes
What this study did
NCT05243628 · Mannkind Corporation
2022-03-31 – 2022-10-17 · Type 1 Diabetes
What this study did
Other / comorbidity
NCT06939959 · Khyber Teaching Hospital
2025-04-14 – 2026-04-25 · Dry Eye, Insulin Sensitivity
What this study did
NCT04030091 · Sciema UG
2019-09-06 – 2020-12-31 · Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
What this study did
NCT01630369 · Sanofi
2012-02 – 2013-05 · Type 2 Diabetes Mellitus
What this study did
NCT00359801 · Pfizer
2006-07 – 2009-04 · Diabetes Mellitus
What this study did
Early phase / not applicable (3)
Other / comorbidity
NCT07582471 · Dr Mudassar Saeed Pansota
2025-10-08 – 2026-04-07 · Gestational Diabetes Mellitus (GDM)
What this study did
NCT01307306 · Sunnybrook Health Sciences Centre
2011-03 – 2018-03 · Burns
What this study did
NCT00625781 · Region Örebro County
2008-02 – 2013-12 · Impaired Glucose Tolerance, Fetal Macrosomia
What this study did
Used as active comparator (5)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 1/2 (2)
Other / comorbidity
NCT02324309 · Biodel
2014-05 – 2014-11 · Diabetes Mellitus
What this study did
NCT02212951 · Biodel
2014-05 – 2014-07 · Type 2 Diabetes Mellitus
What this study did
Phase 1 (3)
Other / comorbidity
NCT07364669 · Laboratorios Pisa S.A. de C.V.
2024-10-24 – 2025-05-07 · Healthy Subjects
What this study did
NCT04022317 · Biocon Limited
2019-06-18 – 2019-09-20 · Healthy Volunteer
What this study did
NCT01511159 · Novo Nordisk A/S
2001-10 – 2001-12 · Diabetes, Healthy
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Early phase / not applicable (1)
Type 1 Diabetes
NCT05095259 · Nordsjaellands Hospital
2019-12-16 – 2023-12 · Type1diabetes
What this study did

Competitive landscape

2 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Type 1 Diabetes: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Insulin Human: this drugApproved—Insulinnot yet gradedNo reviewed efficacy summary in this indication
AfrezzaApprovedPeptideInsulinPartial signal
NCT04974528: HbA1c change at week 26 (ITT, n=117 vs 113): Afrezza +0.19 vs rapid-acting insulin analog +0.01; difference 0.18 percentage points (95% CI -0.07 to 0.44); non-inferiority (0.4% margin) not met, one-sided adjusted p=0.058. missed
NCT01445951: Change in HbA1c from baseline to week 24 (LS mean): Technosphere Insulin (Gen2 inhaler) plus basal insulin -0.21% vs insulin aspart plus basal insulin -0.40%; difference 0.19% (95% CI 0.02 to 0.36), inside the pre-specified non-inferiority margin of 0.4% (CT.gov posted analysis).
Insulin Aspart (NovoLog)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Aspart (Fiasp)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Degludec (Tresiba)ApprovedPeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
Insulin Detemir (Levemir)
ApprovedUS marketing discontinued
PeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
Insulin Glargine (Lantus)ApprovedPeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
Insulin Glargine (Basaglar)ApprovedPeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
Insulin Glargine (Toujeo)ApprovedPeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
Insulin Glulisine (Apidra)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Lispro (Humalog)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Lispro (Lyumjev)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin NPH (Humulin N)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Pramlintide (Symlin)
ApprovedUS marketing discontinued
PeptideAmylin receptornot yet gradedNo reviewed efficacy summary in this indication
CadisegliatinPhase 3Small moleculeGlucokinasenot yet gradedNo reviewed efficacy summary in this indication
ORMD-0801
Phase 3(overall)
PeptideInsulin
Partial signal(overall)
No reviewed efficacy summary in this indication
Sotagliflozin (Inpefa)Phase 3Small moleculeSGLT1/2 (dual)not yet gradedNo reviewed efficacy summary in this indication
ZimislecelPhase 3Cell therapyPancreatic islet cells (VX-880 is a stem cell-derived therapy, not a small molecule drug), Pancreatic islet cell replacementnot yet gradedNo reviewed efficacy summary in this indication
IcovamenibPhase 2Small moleculeMeninnot yet gradedNo reviewed efficacy summary in this indication

Compare side by side

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Insulin human to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
December 2028 (1)
Phase 1Insulin Resistance, Hyperinsulinemia, Metabolic Dysfunction Associated Steatotic Liver Disease, Non-Alcoholic Fatty Liver Disease …Not yet recruiting
Est. primary completion 2028-12-31 · NCT06558422 · CT.gov ↗
What to watch

See the full readout calendar ↗